Score Breakdown
Decent.
Insmed is executing one of the most impressive rare disease drug launches in history with BRINSUPRI, targeting $1B+ in its first full year for a disease with no approved competition. ARIKAYCE provides a stable base with potential ENCORE upside. However, the stock at $139 and $30B market cap already prices in substantial success — requiring roughly $2.5B+ in peak revenue with strong margins to justify valuation. The BiRCh CRS failure capped the multi-indication optionality story, insider selling is concerning, and the company still burns ~$1B/year with only 17 months of cash runway. At 49x TTM sales with massive ongoing dilution (19% annualized), the risk/reward is roughly balanced. The path to profitability is visible but not yet proven, and any stumble in BRINSUPRI uptake or the ENCORE readout could trigger significant downside. The stock is fairly valued for a base case scenario but offers limited margin of safety.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Slow bleed.
No data.
Tight but ok.
Some skeptics.
Decent.
🐻 Why Bears Hate It
The core bear case centers on elusive profitability and high cash burn despite record revenue. Insmed's net loss widened to $6.42 per share for FY2025, a significant deterioration from FY2024. The company's 'win streak' in clinical trials was broken by the BiRCh failure, raising skepticism about the drug's ceiling beyond the NCFB indication. Critics argue that at a Price-to-Book ratio of ~32x—massively higher than the biotech sector average of 2.5x—the stock is priced for perfection, leaving little room for error in the 2026 launch of Brinsupri (Simply Wall St, 2025).
🔍 What's In The SEC Filings
Insmed is a high-stakes equity-financing vehicle with a $5.6 billion accumulated deficit, facing a short runway despite recent massive capital raises.
Aggressive equity dilution and convertible debt conversion.
“After April 24, 2025, holders of $567.5 million of aggregate principal amount of the then outstanding 2028 Convertible Notes elected to convert... resulting in the issuance of an aggregate of 17,756,196 shares.”
The company relies on continuous common stock issuance and conversion of debt to fund a massive burn rate, increasing outstanding shares from 179 million to 214 million in a single fiscal year.
Accounts Receivable growth significantly outpaced revenue growth.
“Accounts receivable [Dec. 31, 2025] 140,857, [Dec. 31, 2024] 52,012.”
AR increased by 171% while net product revenues only increased by 67% ($606.4M vs $363.7M). This suggests potentially aggressive end-of-year channel loading or deteriorating collection quality.
Unsustainable cash burn relative to total liquidity.
“The Company... reported a net loss of $1,276.8 million for the year ended December 31, 2025... Net cash used in operating activities [-] $935,014 [thousand].”
With a cash/securities balance of $1.43 billion and a nearly $1 billion annual operating cash burn, the company has approximately 1.5 years of runway without further dilutive financing.
Massive P&L impact from Level 3 liability revaluations.
“Change in fair value of deferred and contingent consideration liabilities [2025] 251,993 [thousand].”
The company recognized a quarter-billion dollar non-cash expense purely based on internal probability models for milestones. This volatility masks core operational results and creates potential for future earnings management.
Coordinated adoption of Rule 10b5-1 plans by multiple executives in Q4.
“The following table describes the written plans... adopted or terminated by our officers and directors... Michael Smith (CLO), Sara Bonstein (CFO), S. Nicole Schaeffer (CPSO), Roger Adsett (COO).”
Nearly the entire C-suite adopted new selling plans in November/December 2025, signaling a lack of confidence in the current share price or an expectation of further dilution.
Intrinsic value is heavily compromised by the 215M share count and the $372M in contingent liabilities. A valuation must discount for a 100% probability of further dilution in 2027.
The 'Royalty Financing Agreement' with OrbiMed acts as a synthetic debt instrument with an effective interest rate of 12.4%, significantly higher than traditional debt, effectively siphoning off 4.5% of ARIKAYCE global sales.